<DOC>
	<DOCNO>NCT00171210</DOCNO>
	<brief_summary>A 1-year randomized Phase III core trial ( NCT00061750 ) use deferoxamine comparator conduct investigate efficacy deferasirox regularly transfused patient β-thalassemia 2 year age old . Patients successfully complete main trial may continue extension trial receive chelation therapy deferasirox additional 4 year . The objective study assess efficacy long-term safety deferasirox regularly transfused patient β-thalassemia 2 year age old .</brief_summary>
	<brief_title>An Extension Study Iron Chelation Therapy With Deferasirox ( ICL670 ) β-thalassemia Patients With Transfusional Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Inclusion criterion Patients complete 12month core study ( NCT00061750 ) Female patient menarche sexually active , use doublebarrier contraception , oral contraceptive plus barrier contraceptive , undergone clinically document total hysterectomy and/or ovariectomy , tubal ligation Written inform consent obtain patient and/or legal guardian patient 's behalf accordance national legislation Exclusion criterion Pregnant breast feeding patient Patients history noncompliance medical regimen consider potentially unreliable</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>β-thalassemia</keyword>
	<keyword>iron overload</keyword>
	<keyword>deferasirox</keyword>
</DOC>